Inhibition of autophagy genes in cancer chemotherapy
AssigneeBritish Columbia Cancer Agency
InventorsSharon Margaret Gorski, Mohammad Abdul Qadir
Life of this patent
Estimating the term…
Abstract
There is provided compositions and methods for improving the therapeutic efficacy of various cancer treatments, for example endocrine therapy, chemotherapy or radiation therapy, by inhibiting the expression of one or more genes involved in the cellular autophagy response. The compositions include compositions comprising an siRNA directed against an Atg gene and may be used to inhibit expression of an Atg gene in a cell currently undergoing cancer therapy, or to treat, inhibit or prevent cancer in a subject in combination with a cancer therapy.
Claims7
A method of increasing a cellular response to a cancer therapy comprising inhibiting expression of a Beclin 1 (Atg6) gene in a breast cancer cell in a human patient currently undergoing the cancer therapy, wherein the cancer therapy comprises administration of an effective amount of tamoxifen or a taxane, and said inhibiting comprises contacting the cell with an siRNA encapsulated in a liposome in an amount effective to inhibit expression of the Beclin 1 gene.
A method of treating a breast cancer in a human patient in need thereof comprising administering to the patient an siRNA encapsulated in a liposome in an amount effective to inhibit expression of a Beclin 1 (Atg6) gene, in combination with a cancer therapy, wherein the cancer therapy comprises administration of an effective amount of tamoxifen or a taxane.
Dependencies are inferred from the claim text.